BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Diatos S.A. Pre-Clinical Results Published in Clinical Cancer Research


4/1/2008 1:32:05 PM

Paris, France, 1 April 2008 – Diatos SA, an international biopharmaceutical company focusing on the research, development and commercialization of targeted anti-cancer drugs, announced that the peer-reviewed medical journal ‘Clinical Cancer Research’ has today published positive pre-clinical in vivo efficacy and toxicology results concerning DTS-108. The research demonstrated that DTS-108 has greater anti-tumoral efficacy and safety, compared to irinotecan, as a result of an efficient and non-hepatic mode of activation. This leads to significantly higher circulating levels of the active metabolite with reduced gastrointestinal toxicity. In addition, it is anticipated that DTS-108 will bypass the inter-patient variability which is a major limitation in the therapeutic use of irinotecan. This is due to enhanced delivery of the active metabolite by using Diatos’ linker peptide technology, Vectocell®, which safe guards the efficacy whilst reducing the toxic side effects of the anti-cancer product.

Irinotecan is an effective chemotherapeutic agent that is prescribed for advanced colorectal, non-small-cell lung cancer (NSCLC) and small-cell lung cancer (SCLC). The principle side effect of irinotecan is severe (grade 3-4) diarrhoea observed in 30-40% of treated patients. A significant clinical advantage should therefore be gained from the direct administration of the active metabolite, SN38, using a drug delivery technology such as Vectocell®, which delivers higher concentrations of SN38, whilst bypassing the severe side effects.

Commenting on today’s announcement, Jonathan Kearsey, Ph.D, Director of Research at Diatos, said: “The search for cytotoxic molecules with enhanced efficacy and toxicity profiles is essential for improved cancer patient care. This peer-reviewed publication represents another step in the validation of the benefits of DTS-108 versus standard of care treatment.”

“Rapid completion of the preclinical toxicology program is expected to allow Diatos to further evaluate the benefit of DTS-108 and the Vectocell® technology platform in the clinical setting.” He added.


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->